Ikorituzumab receives FDA approval: new hope for lymphoma patients

The U.S. Food and Drug Administration (FDA) has officially approved icorituzumab (trade name: Epkinly) for the treatment of relapsed or refractory diffuse largeB-cell lymphoma (DLBCL) and follicular lymphoma (FL). This landmark approval brings new hope to lymphoma patients who have repeatedly encountered setbacks in traditional treatment options.

Icorelatumumab is an innovative CD3/CD20 bispecific antibody drug jointly developed by AbbVie and Genmab. The drug uses Genmab's proprietary DuoBody technology, which can simultaneously interact with CD3 receptors and < The binding of CD20 antigen on /span>B cell lymphoma cells accurately guides T cells to attack and eliminate CD20 positive lymphoma cells. This unique mechanism of action allows icarelatumumab to demonstrate excellent efficacy in the treatment of refractory lymphoma.

In clinical trials, icorituzumab has demonstrated impressive therapeutic effects. For patients with relapsed or refractory DLBCL, the drug’s overall response rate (ORR) is as high as 61%, and the complete response rate ( pan>CR) also reached 38%, and the median duration of response (DoR) was as long as 15.6 months. For patients with follicular lymphoma, icorituzumab also performed well, with ORR as high as 83% and CRIt is63%, and the median DoR has reached 21.4 months. These data strongly demonstrate the efficacy and durability of icarelatumumab in the treatment of these refractory lymphomas.

In addition to its remarkable efficacy, icarelatumumab also uses subcutaneous injection, which is simpler and faster than traditional intravenous injection, effectively reducing the pain and inconvenience of patients. At the same time, the safety of the drug has been fully verified, and no serious adverse reactions or side effects have been found, providing patients with a safer and more convenient treatment option.

FDA’s approval is undoubtedly a huge blessing for lymphoma patients. For a long time, patients with relapsed or refractory lymphoma have faced the dilemma of limited treatment options and rapid disease progression. Now, with the approval of icorelatumumab, these patients will have the opportunity to receive this innovative treatment, thereby improving prognosis and prolonging survival.

References:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma